𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

✍ Scribed by Daniel J. Lovell; Andreas Reiff; Norman T. Ilowite; Carol A. Wallace; Yun Chon; Shao-Lee Lin; Scott W. Baumgartner; Edward H. Giannini

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
114 KB
Volume
58
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Long-term safety and efficacy of etanerc
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis
✍ Daniel J. Lovell; Andreas Reiff; Olcay Y. Jones; Rayfel Schneider; James Nocton; πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 104 KB πŸ‘ 2 views

## Abstract ## Objective Previous studies showed that etanercept treatment in patients with polyarticular‐course juvenile rheumatoid arthritis (JRA) provided rapid clinical improvement that was sustained for up to 2 years. The goal of our study was to provide data on safety and efficacy after 4 ye

Therapy of patients with rheumatoid arth
Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept
✍ Buch, Maya H. ;Bingham, Sarah J. ;Bejarano, Victoria ;Bryer, Domini ;White, Jo ; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 2 views

## Abstract ## Objective The role of alternative tumor necrosis factor (TNF) antagonist therapies in the context of failure of initial TNF antagonist therapy in patients with rheumatoid arthritis (RA) has yet to be clearly defined. The goal of this study was to determine the efficacy of etanercept

The efficacy and safety of leflunomide i
The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year followup study
✍ J. R. Kalden; M. Schattenkirchner; H. SΓΆrensen; P. Emery; C. Deighton; B. Rozman πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 123 KB πŸ‘ 1 views

## Abstract ## Objective To investigate the efficacy and safety of leflunomide beyond 2 years in a multinational, open‐label extension of 2 phase III double‐blind studies. ## Methods Patients with rheumatoid arthritis (RA) who received leflunomide (100 mg/day for 3 days, 10 mg/day or 20 mg/day t